

**Cancer Prevention and Research Institute of Texas**  
**Quarterly Financial Report**  
As of August 31, 2023

**Indirect Administration (B.1.1.)**

	<b>2023 Appropriated</b>	<b>2023 Budgeted</b>	<b>% of Total Budget</b>	<b>Actual Expenditures &amp; Grant Encumbrances (FYTD)</b>	<b>Remaining Budget</b>	<b>Percent Expended</b>	<b>Estimated Expenditures (YTD)</b>	<b>Lapse/Overspent</b>
1001 Salaries and Wages	\$ 1,847,425	\$ 1,824,970		\$ 1,734,826	90,144	95%	\$ 1,734,826	\$ 90,144
1002 Other Personnel Costs	38,785	47,056		47,056	0	100%	47,056	0
2001 Professional Fees and Services	1,038,960	1,227,490		1,207,030	20,460	98%	1,207,030	20,460
2003 Consumable Supplies	24,000	24,000		4,037	19,963	17%	4,037	19,963
2004 Utilities	58,600	58,600		27,939	30,661	48%	27,939	30,661
2005 Travel	45,000	45,000		44,576	424	99%	44,576	424
2006 Rent-Building	11,000	11,000		3,295	7,705	0%	3,295	7,705
2007 Rent-Machine and Other	39,172	39,172		22,812	16,360	58%	22,812	16,360
2009 Other Operating Expenses	1,807,951	1,897,359		972,341	925,018	51%	972,341	925,018
<b>Subtotal - Indirect Administration (B.1.1.)</b>	<b>\$ 4,910,893</b>	<b>\$ 5,174,647</b>	<b>1.74%</b>	<b>\$ 4,063,912</b>	<b>\$ 1,110,735</b>	<b>79%</b>	<b>\$ 4,063,912</b>	<b>\$ 1,110,735</b>

**Grant Review and Award Operations (A.1.3.)**

	<b>2023 Appropriated</b>	<b>2023 Budgeted</b>	<b>% of Total Budget</b>	<b>Actual Expenditures &amp; Grant Encumbrances (FYTD)</b>	<b>Remaining Budget</b>	<b>Percent Expended</b>	<b>Estimated Expenditures (YTD)</b>	<b>Lapse/Overspent</b>
1001 Salaries and Wages	\$ 3,505,873	4,035,375		\$ 4,035,375	\$ (0)	100%	\$ 4,035,375	\$ (0)
1002 Other Personnel Costs	45,000	112,944		112,944	0	0%	112,944	0
2001 Professional Fees and Services	12,420,663	11,913,217		11,913,217	0	100%	11,913,217	0
2003 Consumable Supplies	-	-		-	-	0%	-	-
2004 Utilities	12,000	17,674		17,674	0	100%	17,674	0
2005 Travel	45,000	25,000		22,896	2,104	92%	22,896	2,104
2009 Other Operating Expenses	70,359	221,095		29,368	191,726	13%	29,368	191,726
<b>Subtotal - Grant Operations (A.1.3.)</b>	<b>\$ 16,098,895</b>	<b>\$ 16,325,305</b>	<b>5.49%</b>	<b>\$ 16,131,473</b>	<b>\$ 193,831</b>	<b>99%</b>	<b>\$ 16,131,473</b>	<b>\$ 193,831</b>

**Grants**

	<b>2023 Appropriated</b>	<b>2023 Budgeted</b>	<b>% of Total Budget</b>	<b>Actual Expenditures &amp; Grant Encumbrances (FYTD)</b>	<b>Remaining Budget</b>	<b>Percent Expended</b>	<b>Estimated Expenditures (YTD)</b>	<b>Lapse/Overspent</b>
4000 Grants - Prevention (A.1.2)	\$ 27,671,780	\$ 27,718,402		\$ 26,920,426	\$ 797,976	97%	\$ 26,920,426	\$ 797,976
4000 Grants - Research (A.1.1.)	248,251,400	\$ 248,251,400		242,119,006	\$ 6,132,394	98%	242,119,006	6,132,394
<b>Subtotal - Grants</b>	<b>\$ 275,923,180</b>	<b>\$ 275,969,802</b>	<b>92.77%</b>	<b>\$ 269,039,432</b>	<b>\$ 6,930,370</b>	<b>97%</b>	<b>\$ 269,039,432</b>	<b>\$ 6,930,370</b>
<b>Grand Totals</b>	<b>\$ 296,932,968</b>	<b>\$ 297,469,753</b>	<b>100.00%</b>	<b>\$ 289,234,817</b>	<b>\$ 8,234,937</b>	<b>97%</b>	<b>\$ 289,234,817</b>	<b>\$ 8,234,937</b>

**Cancer Prevention and Research Institute of Texas  
Cancer Prevention and Research Institute Fund Account - 5136  
As of August 31, 2023**

	<b>08/01/2023- 08/31/2023</b>	<b>AY 23 Year to Date as of 08/31/2023</b>
<b>Beginning Balance : 9/01/2022</b>		<b>\$ 600,506</b>
<b>Increases:</b>		
(1)	\$ -	\$ -
(2)	-	
<b>Total Increases</b>	<b>\$ -</b>	<b>\$ 600,506.00</b>
<b>Reductions:</b>		
Expenditures - Appropriated	\$ -	\$ -
	\$ -	\$ -
	\$ -	\$ -
<b>Total Reductions</b>	<b>\$ -</b>	<b>\$ -</b>
<b>Ending Balance: 08/31/2023</b>		<b>\$ 600,506.00</b>

Note: (1) The Institute received a settlement from the Texas Cancer Coalition (TCC). This amount represents the final distribution and transfer of all funds (\$303,877) from the TCC which ceased operations in May 2013. These funds are in the State Treasury but are not appropriated to CPRIT. The beginning balance reflects the transfer of all TCC funds.

**Cancer Prevention and Research Institute of Texas  
License Plate Trust Fund Account - 0802  
As of August 31, 2023**

	<b>08/01/2023- 08/31/2023</b>	<b>AY 23 Year to Date as of 08/31/2023</b>
<b>Beginning Balance : 9/01/2022</b>		<b>\$ 46,621.77</b>
<b>Increases:</b>		
(1) License Plate Revenue Received	\$ 672.82	\$ 6,764.91
Interest	\$ 194.98	\$ 1,758.03
<b>Total Increases</b>	<b>\$ 867.80</b>	<b>\$ 55,144.71</b>
<b>Reductions:</b>		
Expenditures - Appropriated	\$ -	\$ -
	-	-
<b>Total Reductions</b>	<b>\$ -</b>	<b>\$ -</b>
<b>Ending Balance: 08/31/2023</b>		<b>\$ 55,144.71</b>

Note:

Balance forward from 2022 License Plate \$46,621.77

**Cancer Prevention and Research Institute of Texas**

**Appropriated Receipts - 666**

**As of August 31, 2023**

	<u>08/01/2023-</u> <u>08/31/2023</u>	<u>AY 23 Year to Date as of</u> <u>08/31/2023</u>
<b><u>Beginning Balance : 9/01/2022</u></b>		<b>\$ 34,246.90</b>
<b>Increases:</b>		
(1) Product Development Application Fees Received	\$ 2,000.00	\$ 21,000.00
(2) Conference Registration Fees	\$ 74,650.00	\$ 187,797.75
(3) Conference Registration Fees-Credit Card	\$ 1,869.22	\$ 4,364.93
<b>Total Increases</b>	<b><u>\$ 78,519.22</u></b>	<b><u>\$ 213,162.68</u></b>
<b>Reductions:</b>		
Conference Expenditures - Appropriated	\$ -	\$ -
Credit Card Fees Expended	\$ -	\$ -
Refund-Application Fees	\$ -	\$ -
Legal Services Expenses (Application Fees)	\$ -	\$ -
<b>Total Reductions</b>	<b><u>\$ -</u></b>	<b><u>\$ -</u></b>
<b><u>Ending Balance: 08/31/2023</u></b>		<b><u>\$ 247,409.58</u></b>

Forward balance for FY 2022 is \$34,246.90  
Application Fees

**Cancer Prevention and Research Institute of Texas**  
**Interest & Sinking Fund Account - 5168**  
**As of August 31, 2023**

	<b>08/01/2023- 08/31/2023</b>	<b>AY 23 Year to Date as of 08/31/2023</b>
<b>Beginning Balance : 9/01/2022</b>		<b>\$ 4,467,549.58</b>
<b>Increases:</b>		
(1) Revenue Sharing / Royalties	\$ 102,481.91	\$ 1,923,056.43
	\$ -	
<b>Total Increases</b>	<b>\$ 102,481.91</b>	<b>\$ 6,390,606.01</b>
<b>Reductions:</b>		
Expenditures - Appropriated	\$ -	\$ -
	\$ -	
	\$ -	\$ -
<b>Total Reductions</b>	<b>\$ -</b>	<b>\$ -</b>
<b>Ending Balance: 08/31/2023</b>		<b>\$ 6,390,606.01</b>

Balance forward from FY 2022 is \$4,467,549.58